PARP1-Inhibition Sensitizes Cervical Cancer Cell Lines for Chemoradiation and Thermoradiation

SIMPLE SUMMARY: Five-year survival rates from patients with locally advanced cervical cancer (LACC) are between 40% and 60%. These patients are usually treated with chemoradiation or radiotherapy in combination with hyperthermia (thermoradiation). The aim of our study was to enhance chemoradiation o...

Descripción completa

Detalles Bibliográficos
Autores principales: IJff, Marloes, van Bochove, Gregor G. W., Whitton, Denise, Winiarczyk, Roy, Honhoff, Celina, Rodermond, Hans, Crezee, Johannes, Stalpers, Lukas J. A., Franken, Nicolaas A. P., Oei, Arlene L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8123631/
https://www.ncbi.nlm.nih.gov/pubmed/33926008
http://dx.doi.org/10.3390/cancers13092092

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8123631/
https://www.ncbi.nlm.nih.gov/pubmed/33926008
http://dx.doi.org/10.3390/cancers13092092

Ejemplares similares